Treatment of Carcinoid Syndrome with High Symptom Burden and Carcinoid Heart Disease

Not all presentations of carcinoid syndrome follow the same clinical course. When symptom burden is elevated and structural cardiac involvement is present, the management approach differs substantially from milder, stable disease.

This clinical scenario is defined by one or more of the following features: more than four bowel movements per day and/or more than five flushing episodes per day, active tumour progression, hepatic tumour burden greater than 50%, and/or carcinoid heart disease. Any of these criteria place the presentation in the aggressive category requiring escalated management.

Approach: Management in this aggressive setting involves targeted systemic or immunomodulatory options — with somatostatin analogue therapy continued throughout. The complete sequencing, decision criteria, and clinical algorithm are available in the full protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/jne.13146

RCS may be divided into either non-aggressive or aggressive, based on symptoms burden (< or ≥ 4 BM/day, and/or < or ≥ 5 flushing episodes/day, respectively) together with disease stability (stable or progressive), hepatic burden (< or ≥ 50% liver involvement), and/or the presence of CHD.
Aggressive: high symptom burden, tumor progression, hepatic tumour burden > 50% and/or CHD.
Aggressive CS: more than four bowel movements (BM)/day and/or more than five flushing episodes/day.
Everolimus · Interferon

View source ↗